Devices/Recall·openFDA/device

Remel, Inc — Class II: Yeastone Broth, 11ML, 10/BOX YY3462

MediumPublished Apr 22, 2026· AI-analyzed May 4, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Remel, Inc has initiated a Class II recall for Yeastone Broth (Catalog YY3462) due to reports of incorrect Antimicrobial Susceptibility Testing (AST) results during quality control procedures.

Who it affects

This affects Remel, Inc, clinical microbiology laboratories utilizing Yeastone Broth for antifungal susceptibility testing, and healthcare providers relying on these diagnostic results.

Why it matters

Failure of the broth to provide accurate Quality Control results suggests a potential risk to the reliability of clinical diagnostic data. If QC failures are overlooked, there is a risk of delayed treatment or inappropriate selection of antifungal agents, potentially impacting patient outcomes in a clinical setting.

Practical takeaway

Laboratory managers should immediately sequester the affected lot YY3462 and review QC logs for discrepancies in AST results. Quality Assurance teams should evaluate if any clinical results were released despite failed QC and initiate necessary communication with clinical staff.

FDA source material

Class II. Reason: Products may report incorrect AST results during quality control. Health consequences may include delayed response or the need to change to another antifungal agent if laboratory ignores Quality Control test result.. Product: Yeastone Broth, 11ML, 10/BOX YY3462. Firm: Remel, Inc (Lenexa KS United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.